Transdermal versus subcutaneous leuprolide: A comparison of acute pharmacodynamic effect
| Autor: | B. Robert Meyer, Vivian O'Mara, Dan Sibalis, Sanford Rosen, James Eschbach, Willi Kreis |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Pharmacology
Agonist business.industry medicine.drug_class Injections Subcutaneous Area under the curve Antineoplastic Agents Luteinizing Hormone Peptide hormone Administration Cutaneous Gonadotropin-Releasing Hormone Pharmacodynamics Anesthesia Humans Medicine Testosterone Pharmacology (medical) Leuprolide Adverse effect Luteinizing hormone business Hormone Transdermal |
| Zdroj: | Clinical Pharmacology and Therapeutics. 48:340-345 |
| ISSN: | 1532-6535 0009-9236 |
| DOI: | 10.1038/clpt.1990.161 |
| Popis: | Transdermal administration of peptides has been limited by the barrier properties of the skin. We compared the acute luteinizing hormone (LH) response to subcutaneous and transdermal administration of an LH-releasing hormone agonist (leuprolide). Eighteen volunteers received 5 mg leuprolide added to electrically powered patches delivering a current of 0.22 μA (transdermally). One week later, they received a 5 mg subcutaneous dose. LH response was measured. The area under the curve for LH response, maximum LH response, and time to maximum LH response were similar. Time to first response was shorter (147 ± 108 minutes [transdermally] and 73 ± 74 minutes [subcutaneously]; p < 0.05), and the area under the curve for the first 150 minutes was greater (3655 ± 2246 mIU · min/ml [transdermally] and 8666 ± 4067 mIU · min/ml [subcutaneously]; p< 0.05) for subcutaneous delivery. No major adverse effects were seen. This electrically powered transdermal technique merits further study. Clinical Pharmacology and Therapeutics (1990) 48, 340–345; doi:10.1038/clpt.1990.161 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text